Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015124974> ?p ?o ?g. }
- W2015124974 endingPage "616" @default.
- W2015124974 startingPage "606" @default.
- W2015124974 abstract "Background Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. It reduces proteinuria in patients with glomerular disease, although its impact on glomerular filtration rate (GFR) is unknown. We hypothesized that pentoxifylline would slow the estimated GFR decrease in patients with chronic kidney disease at high risk of progression. Study Design Pilot randomized double-blind placebo-controlled trial. Setting & Participants 40 outpatients with decreased GFR, hypertension, and proteinuria greater than 1 g/24 h currently treated with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination and followed up in a nephrology clinic at a tertiary medical care facility. Intervention Pentoxifylline, 400 mg twice daily, or matching placebo. Outcomes Difference in rates of estimated GFR change during the 1-year study period between the 2 groups. Measurements Estimated GFR (4-variable Modification of Diet in Renal Disease Study equation) and proteinuria by 24-hour urine collection were assessed at baseline and 6 and 12 months after enrollment. Results Baseline characteristics were similar between the 2 groups. At 1 year, the mean estimated GFR decrease was significantly less in the pentoxifylline group than the placebo group (−1.2 ± 7.0 versus −7.2 ± 8.2 mL/min/1.73 m2/y; mean difference, −6.0 mL/min/1.73 m2/y; 95% confidence interval, −11.4 to −0.6; P = 0.03). For pentoxifylline-treated participants, the mean estimated GFR decrease during treatment was slower compared with the year before study enrollment (−9.6 ± 11.9 mL/min/1.73 m2/y; mean difference, −8.4 mL/min/1.73 m2/y; 95% confidence interval, −14.8 to −2.1; P = 0.01). Proteinuria was not different between the pentoxifylline and placebo groups at baseline, 6 months, or 1 year. Limitations Small sample size and incomplete follow-up. Conclusions Pentoxifylline may slow the estimated GFR decrease in high-risk patients. This may be independent of its antiproteinuric properties and warrants further investigation. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. It reduces proteinuria in patients with glomerular disease, although its impact on glomerular filtration rate (GFR) is unknown. We hypothesized that pentoxifylline would slow the estimated GFR decrease in patients with chronic kidney disease at high risk of progression. Pilot randomized double-blind placebo-controlled trial. 40 outpatients with decreased GFR, hypertension, and proteinuria greater than 1 g/24 h currently treated with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination and followed up in a nephrology clinic at a tertiary medical care facility. Pentoxifylline, 400 mg twice daily, or matching placebo. Difference in rates of estimated GFR change during the 1-year study period between the 2 groups. Estimated GFR (4-variable Modification of Diet in Renal Disease Study equation) and proteinuria by 24-hour urine collection were assessed at baseline and 6 and 12 months after enrollment. Baseline characteristics were similar between the 2 groups. At 1 year, the mean estimated GFR decrease was significantly less in the pentoxifylline group than the placebo group (−1.2 ± 7.0 versus −7.2 ± 8.2 mL/min/1.73 m2/y; mean difference, −6.0 mL/min/1.73 m2/y; 95% confidence interval, −11.4 to −0.6; P = 0.03). For pentoxifylline-treated participants, the mean estimated GFR decrease during treatment was slower compared with the year before study enrollment (−9.6 ± 11.9 mL/min/1.73 m2/y; mean difference, −8.4 mL/min/1.73 m2/y; 95% confidence interval, −14.8 to −2.1; P = 0.01). Proteinuria was not different between the pentoxifylline and placebo groups at baseline, 6 months, or 1 year. Small sample size and incomplete follow-up. Pentoxifylline may slow the estimated GFR decrease in high-risk patients. This may be independent of its antiproteinuric properties and warrants further investigation." @default.
- W2015124974 created "2016-06-24" @default.
- W2015124974 creator A5008679494 @default.
- W2015124974 creator A5026476454 @default.
- W2015124974 creator A5036690508 @default.
- W2015124974 creator A5045383541 @default.
- W2015124974 creator A5062055687 @default.
- W2015124974 creator A5070718012 @default.
- W2015124974 date "2009-04-01" @default.
- W2015124974 modified "2023-10-16" @default.
- W2015124974 title "Effect of Pentoxifylline on GFR Decline in CKD: A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial" @default.
- W2015124974 cites W1981494429 @default.
- W2015124974 cites W1982341832 @default.
- W2015124974 cites W2003332051 @default.
- W2015124974 cites W2004256445 @default.
- W2015124974 cites W2006724873 @default.
- W2015124974 cites W2008904879 @default.
- W2015124974 cites W2015685909 @default.
- W2015124974 cites W2033645058 @default.
- W2015124974 cites W2044773944 @default.
- W2015124974 cites W2045516356 @default.
- W2015124974 cites W2056976690 @default.
- W2015124974 cites W2063270035 @default.
- W2015124974 cites W2075391935 @default.
- W2015124974 cites W2086124255 @default.
- W2015124974 cites W2090714091 @default.
- W2015124974 cites W2092639174 @default.
- W2015124974 cites W2106173480 @default.
- W2015124974 cites W2106177899 @default.
- W2015124974 cites W2111368185 @default.
- W2015124974 cites W2126572279 @default.
- W2015124974 cites W2130962126 @default.
- W2015124974 cites W2133355304 @default.
- W2015124974 cites W2143633302 @default.
- W2015124974 cites W2153549777 @default.
- W2015124974 cites W2312400976 @default.
- W2015124974 cites W2326273516 @default.
- W2015124974 cites W2615684303 @default.
- W2015124974 cites W3156148333 @default.
- W2015124974 doi "https://doi.org/10.1053/j.ajkd.2008.11.026" @default.
- W2015124974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19216016" @default.
- W2015124974 hasPublicationYear "2009" @default.
- W2015124974 type Work @default.
- W2015124974 sameAs 2015124974 @default.
- W2015124974 citedByCount "71" @default.
- W2015124974 countsByYear W20151249742012 @default.
- W2015124974 countsByYear W20151249742013 @default.
- W2015124974 countsByYear W20151249742014 @default.
- W2015124974 countsByYear W20151249742015 @default.
- W2015124974 countsByYear W20151249742016 @default.
- W2015124974 countsByYear W20151249742017 @default.
- W2015124974 countsByYear W20151249742018 @default.
- W2015124974 countsByYear W20151249742019 @default.
- W2015124974 countsByYear W20151249742020 @default.
- W2015124974 countsByYear W20151249742021 @default.
- W2015124974 countsByYear W20151249742022 @default.
- W2015124974 crossrefType "journal-article" @default.
- W2015124974 hasAuthorship W2015124974A5008679494 @default.
- W2015124974 hasAuthorship W2015124974A5026476454 @default.
- W2015124974 hasAuthorship W2015124974A5036690508 @default.
- W2015124974 hasAuthorship W2015124974A5045383541 @default.
- W2015124974 hasAuthorship W2015124974A5062055687 @default.
- W2015124974 hasAuthorship W2015124974A5070718012 @default.
- W2015124974 hasConcept C126322002 @default.
- W2015124974 hasConcept C126894567 @default.
- W2015124974 hasConcept C142724271 @default.
- W2015124974 hasConcept C159641895 @default.
- W2015124974 hasConcept C204787440 @default.
- W2015124974 hasConcept C27016395 @default.
- W2015124974 hasConcept C27081682 @default.
- W2015124974 hasConcept C2778653478 @default.
- W2015124974 hasConcept C2779561371 @default.
- W2015124974 hasConcept C2779611605 @default.
- W2015124974 hasConcept C2780091579 @default.
- W2015124974 hasConcept C2780404050 @default.
- W2015124974 hasConcept C44249647 @default.
- W2015124974 hasConcept C54847362 @default.
- W2015124974 hasConcept C71924100 @default.
- W2015124974 hasConcept C84393581 @default.
- W2015124974 hasConceptScore W2015124974C126322002 @default.
- W2015124974 hasConceptScore W2015124974C126894567 @default.
- W2015124974 hasConceptScore W2015124974C142724271 @default.
- W2015124974 hasConceptScore W2015124974C159641895 @default.
- W2015124974 hasConceptScore W2015124974C204787440 @default.
- W2015124974 hasConceptScore W2015124974C27016395 @default.
- W2015124974 hasConceptScore W2015124974C27081682 @default.
- W2015124974 hasConceptScore W2015124974C2778653478 @default.
- W2015124974 hasConceptScore W2015124974C2779561371 @default.
- W2015124974 hasConceptScore W2015124974C2779611605 @default.
- W2015124974 hasConceptScore W2015124974C2780091579 @default.
- W2015124974 hasConceptScore W2015124974C2780404050 @default.
- W2015124974 hasConceptScore W2015124974C44249647 @default.
- W2015124974 hasConceptScore W2015124974C54847362 @default.
- W2015124974 hasConceptScore W2015124974C71924100 @default.
- W2015124974 hasConceptScore W2015124974C84393581 @default.
- W2015124974 hasIssue "4" @default.
- W2015124974 hasLocation W20151249741 @default.
- W2015124974 hasLocation W20151249742 @default.